Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cellegy Pharmaceuticals (CLGY) -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (237)	4/3/2002 8:31:26 AM
From: Arthur Radley	Respond to of 322

News this morning...appears they are building up marketing arm for product launch.

To: Sergio H who wrote (237)	4/11/2002 7:58:24 AM
From: Arthur Radley	Respond to of 322

News this morning.... "Cellegy Reports That Nitric Oxide Donors and cGMP Mimetics Inhibit Tumor Cell Metastasis Paper Presented at American Association for Cancer Research Annual Meeting SOUTH SAN FRANCISCO, Calif., April 11 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY - news) announced positive study results on the involvement of nitric oxide (NO) and cGMP (cyclic guanosine monophosphate) mimetics in attenuating the metastasis of cancer cells. The study results were presented April 7th at the American Association for Cancer Research Annual Meeting in San Francisco. The paper's senior author is Charles Graham, Ph.D., a consultant to Cellegy and a researcher at Queen's University in Ontario, Canada. It was presented at the meeting by Lynne Postovit, a Ph.D. student in Dr. Graham's laboratory. Previously, Dr. Graham's group reported that cancer cells (human breast cancer cells, MDA-MB-231 and mouse melanoma cells, B16F10) made resistant to chemotherapeutic agents, 5-fluorouracil and doxorubicin by hypoxia can be re-sensitized if the cells are exposed to nitroglycerin, a nitric oxide donor (see Cellegy press release dated December 18, 2001 at www.cellegy.com). In the more recent studies, Dr. Graham's team expanded these findings by demonstrating that both nitric oxide donors and the cGMP signaling pathway are involved in the regulation of an invasion associated cell surface molecule (urokinase receptor) as well as metastasis.

To: Sergio H who wrote (237)	4/16/2002 1:22:01 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 322

Dow Jones Business News, Thursday, April 11, 2002 at 10:45 Rating reiterations for April 11 from Briefing.com: Company Symbol Brokerage Firm Reiteration Bed Bath & Beyond BBBY Deutsche Bank Buy Westamerica Banc WABC RBC Capital Markets Sector Perform Zions Bancorp ZION RBC Capital Markets Top Pick HPL Tech HPLA RBC Capital Markets Top Pick NMS Commun NMSS RBC Capital Markets Outperform Cellegy Pharma CLGY Gruntal & Co LT/NT Mkt Outprfm EMCORE EMKR Prudential Buy Sears Roebuck S Prudential Buy Brown & Brown BRO SunTrust Robinson Humphrey Buy Duane Reade DRD SunTrust Robinson Humphrey Buy NMS Commun NMSS SWS Securities Neutral GlobeSpan Virata GSPN Needham & Co Strong Buy